BridgeMD
New treatment option for Diabetic Kidney Disease
Official title Clinical Outcome of Vinpocetine in Diabetic Nephropathy
ClinicalTrials.gov ID: NCT06441591
What this study is testing
What is Vinpocetine?
Vinpocetine is an investigational medicine, given as an once-daily, being studied as a potential treatment for diabetic kidney disease.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this controlled, randomized, clinical trial is to evaluate the effect of vinpocetine on clinical outcomes on the diabetic nephropathy patients. The following will be evaluated; anthropometrics, kidney functions, glucose panel, lipid panel, ICAM-1, quality of life.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years,
- Type II diabetic patients with CKD stage 3 (eGFR = 30 - 59 ml/min) or stage 4 (eGFR 15-29 ml/min),
- Albumin/Creatinine ratio (ACR): 30 - 300 μg /mg (microalbuminuria),
- Stable standard therapy for at least three months prior to inclusion in the study.
You likely can't join if
- Kidney donor or recipient,
- Active malignancy,
- Pregnancy or breastfeeding,
- Known intolerance or hypersensitivity to VPN,
- Participation in other treatment trials,
- Patients with inadequate liver function (ALT and AST three times greater than the upper normal limits),
See the full eligibility criteria
- Age ≥ 18 years,
- Type II diabetic patients with CKD stage 3 (eGFR = 30 - 59 ml/min) or stage 4 (eGFR 15-29 ml/min),
- Albumin/Creatinine ratio (ACR): 30 - 300 μg /mg (microalbuminuria),
- Stable standard therapy for at least three months prior to inclusion in the study.
- Kidney donor or recipient,
- Active malignancy,
- Pregnancy or breastfeeding,
- Known intolerance or hypersensitivity to VPN,
- Participation in other treatment trials,
- Patients with inadequate liver function (ALT and AST three times greater than the upper normal limits),
- Patients with severe comorbidities
- Patients receiving warfarin
The study team makes the final eligibility decision.
Where it's taking place
- Cairo, Abbasseia, Egypt
- Cairo, Abbasseya, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Cairo, Abbasseia, Egypt; Cairo, Abbasseya, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.